CAS SIBS group improves synthesis of pristinamycin II by metabolic engineering

The group of JIANG Weihong at CAS SIBS in Shanghai achieved higher yields of pristinamycin, a S. pristinaespiralis antibiotic which can be used to treat MRSA infections, by an increase of gene copy numbers, metabolic engineering and absorption of the product in a macroporous resin. Yields were improved from 185 mg/L to over 1 g/L.

CAS news release, March 2, 2015

CAS SIBS group improves synthesis of pristinamycin II by metabolic engineering
Scroll to top